ER+ mBC: Key insights from the latest EMERALD subgroup analyses

Описание: In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.

Key topics include

Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET

Clinical implications of the EMERALD post-hoc subgroup analyses

Review of elacestrant's safety profile


Clinical takeaways

Duration of prior ET + CDK4/6i of at least 12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer

The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, less then or at least 3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N

Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors

These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression


This video shows the highlights and key clinical takeaways from the conversation. Watch the full version here: https://cor2ed.com/n-connect/programm...


Or listen to the audio version on your favourite podcast platform:
https://podcasts.apple.com/us/podcast....
https://open.spotify.com/episode/4S2A...


This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.


Published March 2025